Table 1 Baseline characteristics of the benign prostatic hyperplasia(BPH) and prostate cancer (PCa) patients

Age (year)

67(62–73)

69(62–74)

67(61–72)

BMI (Kg/m²)

24.74(22.72–26.67)

24.57(22.39–26.56)

24.82(23.03–26.73)

ALB (g/L)

41.2(39.10–43.30)

40.6(38.60–42.90)

41.5(39.60–43.50)

ALP (U/L)

63.3(53.9–75.1)

63.2 (53.9–74.5)

63.5(53.9–75.5)

CKMB (U/L)

13.6(10.7–16.5)

13.1(1.1–16.1)

13.9(11.20-16.78)

fPSA (ng/ml)

0.71(0.26–1.60)

0.82(0.38–1.68)

0.64(0.16–1.54)

tPSA (ng/ml)

5.24(1.68–12.40)

4.48(2.00-9.81)

6.16(1.34–14.90)

f/tPSA

0.15(0.09–0.24)

0.19(0.13–0.25)

0.11(0.07–0.21)

Na (mmol/L)

142.7(141.2-144.1)

142.6(141.1–144.0)

142.8(141.3-144.1)

Ca (mmol/L)

2.23(2.17–2.30)

2.22(2.16–2.28)

2.25(2.19–2.32)

Cl (mmol/L)

104.4(102.4-106.4)

104.6(102.4-106.7)

104.4(102.3-106.2)

P (mmol/L)

1.12(1.01–1.23)

1.09(0.98–1.19)

1.15(1.04–1.28)

fCa (mmol/L)

1.15(1.11–1.18)

1.14(1.10–1.17)

1.15(1.12–1.18)

LDH (U/L)

150.1(134.7-168.6)

150.2(135.2-166.8)

149.9(133.83–169.6)

CK (U/L)

79.8(59.6-107.2)

77.3(57.1–105.0)

82.4(61.7-108.4)

Cre (umol/L)

79.8(71.6–89.4)

79.7(71.7–89.9)

79.9(71.53-89.0)

UA (µmol/L)

328.2(275.8-379.9)

327.6(277.4-383.3)

328.6(274.4-378.8)

TG (mmol/L)

1.14(0.84–1.59)

1.09(0.83–1.51)

1.17(0.85–1.66)

HDL-C (mmol/L)

1.14(0.97–1.36)

1.14(0.95–1.33)

1.15(0.98–1.37)

LDL-C (mmol/L)

2.71(2.25–3.27)

2.62(2.18–3.09)

2.81(2.30–3.40)

Apo-A1 (g/L)

1.25(1.10–1.42)

1.22(1.07–1.39)

1.27(1.12–1.44)

Apo-B (g/L)

0.87(0.74–1.03)

0.85(0.72–0.99)

0.90(0.75–1.06)

K (mmol/L)

4.02(3.81–4.23)

4.03(3.81–4.27)

4.01(3.80–4.21)